

1614
PTO/SB/21 (01-03)Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/600,303
Filing Date	June 20, 2003
First Named Inventor	Frank Wu
Art Unit	1614
Examiner Name	TBD
Attorney Docket Number	ENP-063

Total Number of Pages in This Submission 3

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	13 Referenced Publications
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks _____	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm or Individual	Jason D. Ferrone Reg. No. 52,887
Signature	
Date	9/23/2003

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA on this date: <u>SEPT. 23 2003</u>	
Typed or printed	Stacie S. Capotosto
Signature	
Date	9/23/03

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Or et al. Art Unit : 1614
 Serial No. : 10/600,303 Examiner : TBD
 Filed : June 20, 2003
 Title : Cyclosporin Derivatives for the Treatment of Immune Disorders

Mail Stop Non-Fee Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

The Information Disclosure Statement (form 1449) submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

In addition to those references cited in the USPTO-1449 form submitted herewith, Applicants would like to bring to the Examiner's attention copending, commonly-assigned patent application numbers:

- a. 09/800,856 (filed March 5, 2001);
- b. 09/976,219 (filed October 12, 2001);
- c. 09/975,923 (filed October 12, 2001);
- d. 10/309,934 (filed December 4, 2002); and
- e. 10/360,894 (filed February 7, 2003).

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Alexandria, VA 22313.

SEPT. 23, 2003

Date of Deposit

Stacie S. Capotosto

Signature

Stacie S. CAPOTOSTO

Typed or Printed Name of Person Signing Certificate


Applicant : Or et al.
Serial No. : 10/600,303
Filed : June 20, 2002
Page : Page 2 of 2

Attorney's Docket No.: ENP-063

No fee is believed to be due. In the event that a fee is due please charge Enanta
Pharmaceuticals, Inc., Deposit Account No. 50-2010, referencing Attorney Docket No. ENP-063.

Respectfully submitted,

Date: 9/23/2003



Jason D. Ferrone
Reg. No. 52,887

Enanta Pharmaceuticals, Inc.
Attn: Patent Dept.
500 Arsenal Street
Watertown, MA 02472

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (Rev. 2-32) INFORMATION DISCLOSURE STATEMENT BY APPLICANT Use several sheets if necessary				ATTY. DOCKET NO. ENP-063		SERIAL NO. 10/600,303	
				APPLICANT Frank Wu, <i>et al.</i>			
				FILING DATE June 20, 2003		GROUP 1614	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,554,351	11/19/1985	Wenger et al.	544	177	5/5/1983
	AB	4,798,823	1/17/1989	Witzel et al.	514	11	6/3/1987
	AC	5,239,057	8/24/1993	Wang et al.	530	321	10/15/1991
	AD	5,427,960	6/27/1995	Wang et al.	436	536	10/5/1994
	AE	5,643,870	7/1/1997	Boelsterli et al.	514	11	2/26/1993
	AF	5,827,706	10/27/1998	Leitner et al.	435	183	6/6/1995
	AG	6,605,593 B1	8/12/2003	Naicker et al.	514	11	8/14/2000
	AH	2002/0132763	9/19/2002	Naicker et al.	514	11	11/7/2001

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BA	WO 02/96122	12/21/1988	PCT	C07K	7/64		
	BB	WO 99/18120	4/15/1999	PCT	C07K	7/64		
	BC	WO 99/65933	12/23/1999	PCT	C07K	7/64		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
CA		Billich et al.; Enzymatic Synthesis of CsA, J. Biol. Chem., 262, 17258-17259 (1987).
CB		Faulds et al., Cyclosporin A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Immunoregulatory Disorders, Drugs 45(6), 953-1040;

EXAMINER	DATE CONSIDERED